SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-16-031390
Filing Date
2016-05-10
Accepted
2016-05-10 14:02:54
Documents
42
Period of Report
2016-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q bota20160331_10q.htm 10-Q 792789
2 EXHIBIT 31.1 ex31-1.htm EX-31.1 18471
3 EXHIBIT 31.2 ex31-2.htm EX-31.2 18692
4 EXHIBIT 32.1 ex32-1.htm EX-32.1 12557
  Complete submission text file 0001437749-16-031390.txt   3001380

Data Files

Seq Description Document Type Size
5 EXHIBIT 101.INS avir-20160331.xml EX-101.INS 580307
6 EXHIBIT 101.SCH avir-20160331.xsd EX-101.SCH 27082
7 EXHIBIT 101.CAL avir-20160331_cal.xml EX-101.CAL 31464
8 EXHIBIT 101.DEF avir-20160331_def.xml EX-101.DEF 174073
9 EXHIBIT 101.LAB avir-20160331_lab.xml EX-101.LAB 147090
10 EXHIBIT 101.PRE avir-20160331_pre.xml EX-101.PRE 186879
Mailing Address 2500 NORTHWINDS PARKWAY, SUITE 100 ALPHARETTA 2Q 30009
Business Address 2500 NORTHWINDS PARKWAY, SUITE 100 ALPHARETTA 2Q 30009 301-770-3099
Aviragen Therapeutics, Inc. (Filer) CIK: 0000072444 (see all company filings)

IRS No.: 591212264 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 001-35285 | Film No.: 161635050
SIC: 2836 Biological Products, (No Diagnostic Substances)